OnKure is working closely with several laboratories at the University of Colorado Boulder and Anschutz campuses towards understanding how epigenetic priming, particularly with HDAC inhibition, can impact the molecular mechanisms involved with cancer immune evasion with the goal of identifying novel drug combinations that can be applied to specific indications and patient populations. The Anschutz Medical Campus is also an OnKure Phase-1 clinical partner.

OnKure is working closely with Dr. Gail Eckhart’s laboratories at the University of Texas-Austin, Dell medical School. The collaboration is focused on translating our research into tools and treatments to improve patient health outcomes, with a focus on precision medicine that personalizes cancer treatments based on the latest developments in molecular diagnostics. Dr. Eckhardt’s translational research team is focused on identifying rational combinations of targeted therapies that include epigenetic primers with an emphasis on identifying useful biomarkers for patient stratification.

OnKure entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to support the clinical proof of concept study for MEKTOVI® (binimetinib) in combination with OKI-179, for the treatment of patients with NRAS melanoma. Pursuant to the agreement, Pfizer will provide MEKTOVI for use in the study and OnKure will be responsible for the conduct, and the cost, of the study. OnKure and Pfizer will form a Joint Development Committee to review clinical trial results from the OnKure-sponsored study. The clinical combination trial is targeted to initiate in mid-2021.